重组凝血因子VIIa（诺其）在患有Glanzmann血小板无力症的儿科心脏手术患者中的成功应用。
Successful use of recombinant factor VIIa (NovoSeven) during cardiac surgery in a pediatric patient with Glanzmann thrombasthenia.
作者信息
Yilmaz B T, Alioglu B, Ozyurek E, Akay H T, Mercan S, Ozbek N
机构信息
Department of Pediatrics, Pediatric Hematology Unit, Baskent University Faculty of Medicine, 6.cad No:72/3 06490, Bahcelievler, Ankara, Turkey.
出版信息
Pediatr Cardiol. 2005 Nov-Dec;26(6):843-5. doi: 10.1007/s00246-004-0919-7.
Glanzmann thrombasthenia is a rare, hereditary, congenital disorder of platelet function characterized by inappropriate bleeding that is difficult to control. Recombinant activated factor VII (rFVIIa) is a new treatment that is used to stop bleeding and provide surgical support for these patients. This report describes the use of rFVIIa to prevent serious bleeding during and after open-heart surgery in a child with Glanzmann thrombasthenia.
血小板无力症是一种罕见的遗传性先天性血小板功能障碍，其特征是出血难以控制。重组活化因子VII（rFVIIa）是一种用于止血并为这些患者提供手术支持的新疗法。本报告描述了在一名患有血小板无力症的儿童心脏直视手术期间及术后使用rFVIIa预防严重出血的情况。
Zotero 插件